retatrutide study news 🚨Breaking: Retatrutide's first Phase 3 T2D data just dropped. ▸ A1C: −2.0% at 40 weeks ▸ Weight: −36.6 lbs (−16.8%) at 12 mg ▸ No weight loss plateau — curve still descending June 8, 2026: Reckless physicians

Description

Variants in the GLP1R gene (rs6923761) and GIPR gene (rs1800437) can reveal predispositions in how your body's GLP-1 and glucose-dependent insulinotropic peptide systems function, supporting a more informed conversation with your provider about treatment suitability

[2] Patients should also seek medical review if constipation significantly impacts quality of life or if they find themselves increasingly reliant on stimulant laxatives

Indeed we discovered that the same monotreme Gcg gene encoding GLP-1 is expressed in monotreme gut and venom

Vendor solutions are typically app-driven with telephonic support and may leverage a wireless connected scale or wearable continuous glucose monitors

Given that EtO is a known human carcinogen, the study reinforces the need for updated occupational exposure monitoring and more vigorous enforcement in high-risk industries